11 completed, 3 terminated, 2 unknown, 1 active not recruiting. 18 Phase 2, 6 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 11, Terminated 3, Unknown 2, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 6 | Completed 5, Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Milk Hypersensitivity: new trials by email Literature Review of Milk Hypersensitivity trials Research Report on Milk Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy RPT904, Placebo - Immune System Diseases, Ig-E Mediated Food Allergy | Phase 2 | Active not recruiting | RAPT Therapeutics, Inc., a member of the GSK plc group of companies | 110 | 2025-12-15 | 2026-11-06 |
| Comparison Between a Rush and a Conventional Oral Immunotherapy Protocol to Treat Cow's Milk and Hen´s Egg Allergy. CompITO Study "Rush" regimen, "Conventional" regimen - Food Allergy in Children, Milk Allergy | Phase 2 / Phase 3 | Recruiting | Pablo Rodríguez del Rio | 40 | 2025-06-03 | 2026-02-18 |
| Open-label Extension Study of ADP101 ADP101 - Food Allergy | Phase 1 / Phase 2 | Terminated | Alladapt Immunotherapeutics, Inc. | 45 | 2022-03-14 | 2024-03-26 |
| Dupilumab and Milk OIT for the Treatment of Cow's Milk Allergy Dupilumab, Placebo - Allergies Food Milk | Phase 2 | Terminated | Andrew J Long, PharmD | 33 | 2021-10-18 | 2026-01-07 |
| ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults Low dose ADP101, High dose ADP101, Pooled Placebo - Food Allergy | Phase 1 / Phase 2 | Completed | Alladapt Immunotherapeutics, Inc. | 73 | 2021-04-20 | 2024-05-16 |
| Diagnostic Accuracy and Safety of DBV1605 for the Diagnosis of Non-IgE Mediated Cow's Milk Allergy in Children DBV1605 - Cow's Milk Allergy | Phase 2 | Unknown | DBV Technologies | 230 | 2020-08-28 | 2022-08-11 |
| Baked Milk Oral Immunotherapy for Cow's Milk Allergy Baked non-fat cow's milk powder, Placebo: Tapioca Powder - Cow's Milk Allergy | Phase 2 | Completed | Johns Hopkins University | 41 | 2018-03-15 | 2025-02-04 |
| Impact of Infant Formula on Resolution of Cow's Milk Allergy Lactobacillus GG, Extensively Hydrolyzed Casein Formula, Amino Acid Formula - Milk Allergy | Phase 2 | Terminated | Massachusetts General Hospital | 49 | 2016-02-01 | 2018-07-13 |
| Milk Patch for Eosinophilic Esophagitis Viaskin Milk 500 mcg, Viaskin Placebo - Eosinophilic Esophagitis, Milk Allergy | Phase 2 | Completed | Children's Hospital of Philadelphia | 20 | 2015-10-01 | 2019-07-10 |
| The Effect of Baked Milk on Cow's Milk Allergy Baked Milk - Cow's Milk Allergy | Phase 2 | Completed | Hossein Esmaielzadeh | 100 | 2015-09-01 | 2018-04-25 |
| Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy Viaskin Milk 150 mcg, Viaskin Milk 300 mcg, Viaskin Milk 500 mcg - Food Allergy | Phase 1 / Phase 2 | Completed | DBV Technologies | 198 | 2014-11-01 | 2024-11-20 |
| Evaluation of the Efficacy of a New Infant Formula in Subjects With Cow's Milk Allergy TeHF2013-01 - Cow's Milk Allergy | Phase 2 | Unknown | Federico II University | 29 | 2013-10-01 | 2014-05-29 |
| Free Amino Acid-based Formula to Treat Children Cow's Milk Protein Allergy Amix - Cow's Milk Allergy | Phase 2 | Completed | Edetec Indústria Alimentícia S.A. | 15 | 2013-08-01 | 2015-08-31 |
| OIT and Xolair® (Omalizumab) in Cow's Milk Allergy Placebo for omalizumab, Omalizumab, Milk powder - Milk Allergy | Phase 2 | Completed | Hugh A Sampson, MD | 77 | 2010-08-01 | 2020-08-14 |
| The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy Milk Protein Extract Immunotherapy goal of 4mg/day, Milk Protein Extract Immunotherapy goal of 7mg/day, Milk Powder Immunotherapy goal dose 2000 mg/day - Milk Allergy | Phase 1 / Phase 2 | Completed | Johns Hopkins University | 30 | 2008-08-01 | 2017-05-15 |
| Study of Milk Allergy and Tolerance in Children Baked Milk, Non-baked Milk - Food Hypersensitivity, Milk Hypersensitivity | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 170 | 2008-08-01 | 2016-03-30 |
| A Randomized, Double-Blind, Placebo-Controlled Study of Oral Milk Immunotherapy for Cow's Milk Allergy cow's milk powder, Placebo - Milk Hypersensitivity | Phase 1 / Phase 2 | Completed | Johns Hopkins University | 20 | 2006-08-01 | 2017-04-20 |
| Milk ALLERGY ELIMINATION THROUGH NAET® (Nambudripad's Allergy Elimination Techniques). Procedure - Milk Allergy | Phase 1 / Phase 2 | Completed | Nambudripad's Allergy Research Foundation | 26 | 2005-01-01 | 2006-05-22 |
Food Hypersensitivity (10) · Hypersensitivity (5) · Egg Hypersensitivity (4) · Immune System Diseases (3) · Peanut Hypersensitivity (3) · Hypersensitivity, Immediate (2) · Nut Hypersensitivity (2) · Shellfish Hypersensitivity (2) · Wheat Hypersensitivity (2) · Anaphylaxis (1) · Eosinophilic Esophagitis (1)
Hypersensitivity, Immediate (16) · Immune System Diseases (15) · Hypersensitivity (13) · Food Hypersensitivity (8) · Nut and Peanut Hypersensitivity (3) · Digestive System Diseases (1) · Eosinophilia (1) · Esophageal Diseases (1) · Esophagitis (1) · Gastroenteritis (1) · Gastrointestinal Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Leukocyte Disorders (1)
Drugs, Investigational (1) · Methods (1) · Omalizumab (1) · Refit milk powder (1) · dupilumab (1)
Johns Hopkins University (3) · Alladapt Immunotherapeutics, Inc. (2) · DBV Technologies (2) · Andrew J Long, PharmD (1) · Children's Hospital of Philadelphia (1) · Edetec Indústria Alimentícia S.A. (1) · Federico II University (1) · Hossein Esmaielzadeh (1) · Hugh A Sampson, MD (1) · Massachusetts General Hospital (1) · Nambudripad's Allergy Research Foundation (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Pablo Rodríguez del Rio (1) · RAPT Therapeutics, Inc., a member of the GSK plc group of companies (1)
United States (14) · Canada (3) · Italy (2) · Australia (1) · Iran (1) · Lithuania (1) · Spain (1)
Mei-Lun Wang, MD (2) · Robert Wood, MD (2) · Andrew Long, PharmD (1) · Anna Nowak-Wegrzyn, MD (1) · Antonella Cianferoni, MD, PhD (1) · Devi S Nambudripad, DC,PhD,L.Ac (1) · Hossein Esmaeilzadeh (1) · Hugh A. Sampson, M.D. (1) · Hugh A. Sampson, MD (1) · Robert A Wood, MD (1) · Wayne G Shreffler, MD, PhD (1) · Wendel O Afonso, Master (1)
PMID 33006765, PMID 18951617, PMID 25609353, PMID 26581915, PMID 30027590, PMID 31100455, PMID 38407859, PMID 38814736, PMID 39782691, PMID 41168926
U19AI044236 (1)